Three CRISPR Scientists Win Prestigious Award, Fanning Controversy Over Credit – Scientific American
Scientific American |
Three CRISPR Scientists Win Prestigious Award, Fanning Controversy Over Credit
Scientific American One of the world’s richest science awards, given only in alternate years, will go to three discoverers of the CRISPR-Cas9 genome-editing tool, the Norwegian Academy of Science and Letters announced on Thursday. Emmanuelle Charpentier of the Max … CRISPR Gene Editing Pioneers Win Kavli Prize for NanoscienceQuanta Magazine Kavli Prize to CRISPR ResearchersGenomeWeb Broad’s Feng Zheng snubbed in science awards to CRISPR/Cas9 discoverersSeeking Alpha Laboratory Equipment –GeekWire –UC Berkeley all 12 news articles » |
Drug Discovery & Development |
Approach Could Limit Toxicity of CAR T Therapy in Acute Myeloid Leukemia
Drug Discovery & Development A new approach pioneered at the University of Pennsylvania’s Abramson Cancer Center may provide a new path towards treating Acute Myeloid Leukemia (AML) with CAR T cells. To treat AML, investigators have to target a specific protein – CD33 – that’s … |
MIT Technology Review |
Gene therapy is saving children’s lives—but screening to discover who needs it is lagging behind
MIT Technology Review But as AveXis and other biotech companies race to bring transformative gene therapies to market, states have been slow to adopt screening tests for genetic diseases that are, increasingly, treatable. Newborn screening tests in the US cover a minimum of … |
|
Penn-developed Approach Could Limit Toxicity of CAR T Cell Therapy in Acute Myeloid Leukemia
Newswise (press release) Newswise — PHILADELPHIA – A new approach pioneered at the University of Pennsylvania’s Abramson Cancer Center may provide a new path towards treating Acute Myeloid Leukemia (AML) with CAR T cells. To treat AML, investigators have to target a … |
Medical Xpress |
New approach could limit toxicity of CAR T therapy in acute myeloid leukemia
Medical Xpress A new approach pioneered at the University of Pennsylvania’s Abramson Cancer Center may provide a new path towards treating Acute Myeloid Leukemia (AML) with CAR T cells. To treat AML, investigators have to target a specific protein—CD33—that’s … |